The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines

Blood

Volumn 100, Issue 9, 2002, Pages 3319-3324

  Batova, Ayse ^a   Shao, Li En ^a   Diccianni, Mitchell B ^b   Yu, Alice L ^b   Tanaka, Tetsuya ^c   Rephaeli, Ada ^d   Nudelman, Abraham ^e   Yu, John ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d BAR ILAN UNIVERSITY   (Israel)

^e UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; PIVALOYLOXYMETHYL BUTYRATE; PROTEIN P21;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BURST FORMING UNIT E; CHROMOSOME 11Q; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA;

EID: 0036839093     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0567     Document Type: Article

References (35)

1. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349-352.
2. Allfrey VG, Faulknere R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A. 1964;61:786-794.
3. Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription? Cell. 1997;89:325-328.
4. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210-1216.
5. Brehm A, Nielsen SJ, Miska EA, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 1999;18:2449-2458.
6. Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet. 2000;24:300-303.
7. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukemia. Nature. 1998;391:815-818.
8. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH. Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature. 1998;391:811-814.
9. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A. Distinct interactions of PML-RARalpha and PLZF-RARalpha with corepressors determine differential responses to RA in APL. Nat Genet. 1998;18:126-135.
10. Warrel RP, He L-Z, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 1998;90:1621-1625.
11. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo anti-tumor activity against human tumors. Proc Natl Acad Sci U S A. 1999;96:4592-4597.
12. Suzuki T, Yokozaki H, Kuniyasu H, et al. Effect of trichostatin A on cell growth and expression of cell cycle and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer. 2000;88:992-997.
13. Nudelman A, Ruse M, Aviram A, et al. Novel anticancer prodrugs of butyric acid. J Med Chem. 1992;35:687-694.
14. Aviram A, Rephaeli A, Shaklai M, et al. Effect of butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. J Cancer Res Clin Oncol. 1997;123:267-271.
15. Zimra Y, Maron L. Shaklai M. Nudelman A, Rephaeli A. Pivaloyloxymethyl butyrate (AN-9) exhibits higher anticancer activity than butyric acid (BA): It penetrates faster than the acid and induces apoptosis in HL60 cells. Blood. 1994;84:579a.
16. Rephaeli A. Rabizadeh E, Aviram A, Shaklai M, Ruse M, Nudelman A. Derivatives of butyric acid as potential anti-neoplastic agents. Int J Cancer. 1991;49:66-72.
17. Siu LL, Von Hoff DD, Rephaeli A, et al. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Invest New Drugs. 1998;16:113-119.
18. Zimra Y, Wasserman L, Maron L, Shaklai M, Rephaeli A, Nudelman A. Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL60 cells. J Cancer Res Clin Oncol. 1997;123:152-160.
19. Kasukabe T, Rephaeli A, Honma Y. An anticancer derivative of butyric acid (pivaloyloxymethyl butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukemia cells. Br J Cancer. 1997;75:850-854.
20. Kelner MJ, McMorris TC, Montoya MA, et al. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells. Cancer Chemother Pharmacol. 1997;40:65-71.
21. Marsh W, Center MS. Doxorubicin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells. Cancer Res. 1987;47:5080-5086.
22. LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL. Multidrug resistance in human neuroblastoma cells. J Pediatr Surg. 1991;26:1107-1112.
23. waf1 is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A. 1998;95:6791-6796.
24. Chai F, Evdokiou A, Young GP, Zalewski PD. Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate. Carcinogenesis. 2000;21:7-14.
25. Eckhardt SG, Villalona-Calero MA, Hammond L, et al. A phase I study of AN-9 (pivaloyloxymethyl butyrate. Pivanex™), a lipophilic butyric acid analog, in patients with advanced solid tumors. Proc Am Assoc Cancer Res. 1998;39:507.
26. Singer CRJ, Linch DC, Comparison of the sensitivity of normal and leukaemic myeloid progenitors to in-vitro incubation with cytotoxic drugs: A study of pharmacological purging. Leuk Res. 1987;11:953-959.
27. Spiro TE, Mattelaer M-A, Efira A, Stryckmans P. Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. J Natl Cancer Inst. 1981;66:1053-1059.
28. Linssen P, Brons P, Knops G, Wessels H, de Witte T. Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). Eur J Haematol. 1993;50:149-154.
29. Vaziri C, Stice L, Faller DV. Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ. 1998;9:465-474.
30. Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase). Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 1997;57:3697-3707.
31. Bonnotte B, Favre N, Reveneau S, et al. Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. Cell Death Differ. 1998;5:480-487.
32. Diccianni MB, Omura-Minamisawa M, Batova A, Le T, Bridgeman L, Yu AL. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma. Int J Cancer. 1999;80:145-154.
33. Niitsu N, Kasukabe T, Yokoyama A, et al. Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol Pharmacol. 2000;58:27-36.
34. Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, Phillips DR. Molecular basis for the synergistic interaction of doxorubicin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 2001;61:8194-8202.
35. Zeman SM, Phillips DR, Crothers DM. Characterization of covalent doxorubicin-DNA adducts. Proc Natl Acad Sci U S A. 1998;95:11561-11565.